Emerg Infect Dis by Cheng, Jennifer W. et al.
Burkholderia pseudomallei 
Infection in US Traveler  
Returning from Mexico, 2014
Jennifer W. Cheng, Mary K. Hayden,  
Kamaljit Singh, Ira Heimler, Jay E. Gee,  
Laurie Proia, Beverly E. Sha
Author affiliations: Rush University Medical Center, Chicago,  
Illinois, USA (J.W. Cheng, M.K. Hayden, K. Singh, L. Proia,  
B.E. Sha); Illinois Department of Public Health Laboratories, 
Chicago (I. Heimler); Centers for Disease Control and Prevention, 
Atlanta, Georgia, USA (J.E. Gee)
DOI: http://dx.doi.org/10.3201/eid2110.150815
To the Editor: Melioidosis is an infection with clinical 
manifestations ranging from skin abscess to overwhelming 
sepsis and death. It is caused by Burkholderia pseudomal-
lei, a gram-negative, saprophytic bacillus found in soil and 
water. Melioidosis is highly endemic to Southeast Asia and 
northern Australia, and endemic to the Indian subcontinent, 
southern China, Hong Kong, and Taiwan (1).
The extent of melioidosis in the Western Hemisphere is 
unknown. However, new endemic foci have been identified 
in Puerto Rico and Brazil, and sporadic cases have been 
reported in other parts of the Caribbean, Central America, 
and South America (2–5). Melioidosis is rare in the United 
States; 0–5 cases are reported annually, and most cases oc-
cur in travelers returning from disease-endemic areas (2,3). 
Case clusters have been associated with extreme weather 
events, such as tropical storms or heavy rainfall (5,6). We 
report a case of melioidosis in a returned traveler from Los 
Cabos, Mexico, after Hurricane Odile.
In September 2014, a 59-year-old woman came to a 
hospital in Chicago, Illinois, USA, with a 4-day history of 
right-sided upper back and anterior chest pain, fevers, and 
shortness of breath. She had diabetes mellitus and well-
controlled HIV infection; and had received a cadaveric re-
nal transplant 13 months earlier. Her medications included 
tacrolimus, prednisone, and mycophenolate. She had trav-
eled to Los Cabos, Mexico, 7 days before admission and 
was present when Hurricane Odile hit the area.
On admission to the hospital, her temperature was 
38.5°C, and she had right chest wall tenderness. Her leuko-
cyte count was 22.27 × 103 cells/mL. A computed tomogra-
phy scan of the chest showed an irregular mass in the apical 
segment of the right upper lobe suggestive of a Pancoast 
tumor, with ground glass opacities and an enlarged right 
paratracheal lymph node.
She was given intravenous vancomycin, ceftriaxone, 
and levofloxacin. One of 2 admission blood cultures grew 
gram-negative rods after 30 h incubation, and antimicrobial 
drugs were changed to piperacillin/tazobactam. The isolate 
grew on blood, MacConkey, and chocolate agar when sub-
cultured and was oxidase positive. It was susceptible to 
piperacillin/tazobactam, trimethoprim/sulfamethoxazole, 
and doxycycline but resistant to aminoglycosides and ceph-
alosporins. Pending final identification of the bacterium, 
the patient was discharged on hospital day 5 and was given 
oral doxycycline for presumed bacteremic pneumonia.
The isolate was later identified as B. pseudomallei by 
using phenotype methods and PCR analysis at the Illinois 
Department of Public Health (Chicago, IL, USA) and con-
firmed as B. pseudomallei by the Centers for Disease Con-
trol and Prevention (Atlanta, GA, USA). Genetic analysis 
identified multilocus sequence type 92 and internal tran-
scribed sequence type G, which is consistent with an isolate 
that originated in the Western Hemisphere (7).
Soon afterwards, the patient was readmitted with 
recurrent fevers and chest pain. Blood cultures were 
negative, and a computed tomography scan of the chest 
showed new partial cavitation of the right lung mass. An-
timicrobial drugs were changed to intravenous merope-
nem, and immunosuppressive drugs were reduced. Oral 
doxycycline was added to meropenem after a third admis-
sion for recurrent fevers.
Although current international guidelines recom-
mend a minimum of 10–14 days of intravenous therapy 
for melioidosis (intensive phase), relapse rates are high. 
A newer guideline recommends a longer intensive phase 
for some infections on the basis of results of an ongoing 
study in which longer courses were associated with lower 
relapse rates (8). Given this patient’s recurrent symptoms 
and immunosuppression, we extended her intensive treat-
ment phase to 6 weeks, and she showed subsequent clini-
cal improvement.
Transition to oral eradication-phase therapy was 
complicated by the patient’s allergy to trimethoprim/
sulfamethoxazole, which is considered first-line therapy. 
Because treatment with oral amoxicillin/clavulanate or 
doxycycline has been associated with high relapse rates 
(9), we opted to give our patient combined amoxicillin/
clavulanate and doxycycline to complete 6 months of an-
timicrobial drug therapy. She remains well 10.5 months 
after presentation.
Clinical diagnosis of melioidosis in nonendemic areas 
is challenging because signs of the disease are nonspecific 
and similar to those of more common diseases, such as 
tuberculosis. Laboratory diagnosis is also challenging. In 
this case, B. pseudomallei grew readily in culture. How-
ever, the MicroScan Walk-Away System (Beckman Coulter 
Inc., Brea, CA, USA) or matrix-assisted laser desorption/
ionization time of flight mass spectrometry did not pro-
vide definitive species identification. For this method to be 
potentially useful for identification of B. pseudomallei, the 
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database used would require optimization with addition of 
reference spectra for the organism and its close relatives 
(e.g., B. thailandensis). B. pseudomallei, although differ-
ent from other Burkholderia spp. in its pathogenicity and 
epidemiology, is not easily discriminated from B. thailand-
ensis or B. cepacia complex by using phenotypic tests (10).
In summary, infection with B. pseudomallei should be 
considered in patients with pneumonia after travel to the 
Baja Peninsula in Mexico, and especially after an extreme 
weather event. Because of risk for transmission to laborato-
ry workers and the potential for B. pseudomallei to be used 
for bioterrorism, clinical laboratories should perform only 
limited work up of suspected isolates before referring them 
to a public health laboratory for definitive identification.
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To the Editor: Zika virus (ZIKV) is a mosquito-
borne flavivirus related to yellow fever virus, dengue virus 
(DENV), and West Nile virus (WNV). It is a single-strand-
ed positive RNA virus (10,794-nt genome) that is closely 
related to the Spondweni virus and is transmitted by many 
Aedes spp. mosquitoes, including Ae. africanus, Ae. lu-
teocephalus, Ae. hensilli, and Ae. aegypti. The virus was 
identified in rhesus monkeys during sylvatic yellow fever 
surveillance in the Zika Forest in Uganda in 1947 and was 
reported in humans in 1952 (1).
In 2007, an outbreak of ZIKV was reported in Yap Is-
land, Federated States of Micronesia (2). ZIKV also caused 
a major epidemic in the French Polynesia in 2013–2014 (3), 
and New Caledonia reported imported cases from French 
Polynesia in 2013 and reported an outbreak in 2014 (4).
A new challenge has arisen in Brazil with the emer-
gence of ZIKV and co-circulation with others arboviruses 
(i.e., DENV and chikungunya virus [CHIKV]). We report 
ZIKV infection in Brazil associated with a recent ongoing 
outbreak in Camaçari, Bahia, Brazil, of an illness charac-
terized by maculopapular rash, fever, myalgias/arthralgia, 
and conjunctivitis.
On March 26, 2015, serum samples were obtained 
from 24 patients (Table) at Santa Helena Hospital in Cama-
çari who were given a presumptive diagnosis of an acute 
viral illness by emergency department physicians. These 
patients were given treatment for a dengue-like illness, and 
blood samples were obtained for complete blood counts 
and serologic testing by using an ELISA specific for IgG 
and IgM against DENV.
Serum samples were analyzed at the Federal Univer-
sity of Bahia by reverse transcription PCR (RT-PCR) to 
detect DENV, CHIKV, WNV, Mayaro virus, and ZIKV. 
In brief, serum samples were subjected to RNA extrac-
tion by using the QIAamp Viral RNA Mini Kit (QIAGEN, 
Hilden, Germany). RNA was reverse transcribed by using 
the SuperScript II Reverse Transcription Kit (Invitrogen, 
Carlsbad, CA, USA) and subjected to PCRs specific for 
DENV (5) CHIKV (6), WNV (7) and Mayaro virus (8). 
A positive RT-PCR for a partial region of the envelope 
gene with primers ZIKVENF and ZIKVENVR (positions 
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